INTREXON ACTOBIOTICS N V has a total of 20 patent applications. It decreased the IP activity by 94.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets pharmaceuticals and biotechnology are SHANGHAI BORONG GENE DEV CO, WEINER DAVID and BIOROAD GENE DEV LTD SHANGHAI.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 4 | |
#2 | Australia | 3 | |
#3 | Canada | 3 | |
#4 | China | 3 | |
#5 | WIPO (World Intellectual Property Organization) | 3 | |
#6 | Hong Kong | 1 | |
#7 | Israel | 1 | |
#8 | Republic of Korea | 1 | |
#9 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Steidler Lothar | 20 |
#2 | Vandenbroucke Klaas | 10 |
#3 | Rottiers Pieter | 10 |
#4 | Van Huynegem Karolien | 1 |
Publication | Filing date | Title |
---|---|---|
AU2017328129A1 | Mucoadhesive microorganism | |
WO2018042390A1 | Genetically modified bacteria stably expressing il-10 and insulin | |
CN108883140A | The composition and method for treating type 1 diabetes |